Novel Therapies Shaking Up the Renal Cell Carcinoma Landscape
April 13th 2016Although therapeutic options for renal cell carcinoma have expanded dramatically during the past decade, oncologists are faced with considerable complexity in selecting the right course of treatment for the individual patient.
SPORE Grant Fuels New Research Projects on Neuroendocrine Tumors
April 12th 2016With the FDA emphasis on personalized medicine for patients with orphan diseases, the National Cancer Institute has recently awarded a Neuroendocrine Tumor Specialized Program of Research Excellence to the Holden Comprehensive Cancer Center at the University of Iowa to fund both basic and clinical research on neuroendocrine tumors.
Study Moves T-VEC Into Neoadjuvant Melanoma Setting
April 11th 2016Talimogene laherparepvec (T-VEC; Imlygic), an oncolytic viral immunotherapy approved for patients with melanoma, is being evaluated in a presurgical setting in a phase II clinical trial that may help set the stage for expanding the toolkit of neoadjuvant options for patients with the malignancy.
Oncologists Are Often Slow to Embrace Truly Novel Therapies
April 8th 2016The delivery of antineoplastic therapy via the intravenous route is a long-standing, critical, and well-coordinated component of oncology practice. But what happens when a novel treatment strategy is introduced into the oncology arena that challenges this traditional drug infusion paradigm?
Novel Bladder Cancer Strategies Target PD-1/PD-L1 and VEGF Pathways
March 29th 2016Emerging agents targeting the PD1/PD-L1 pathway and the process of angiogenesis are shaping up to be promising options to break a 30-year drought in new therapies for patients with progressive metastatic urothelial bladder cancer.